Authors
Latest:
The Next Generation of COVID-19 Vaccines and BoostersWill there be an answer to keep the continuously evolving virus at bay? Are seasonal combination vaccines the wave of the future?
Latest:
Lessons in Resilience: What HIV Teaches Us About COVID-19Four lessons learned from the AIDS crisis that can be applied to the fight against our current pandemic.
Latest:
New Antifungal Drug Olorofim Shows Efficacy in Treating Resistant Fungal InfectionsJohn Rex, MD, FACP, discusses the promise, precision, and challenges of this first-in-class antifungal following phase 2b trial results.
Latest:
Second-Generation Antifungal Aims to Address Invasive Fungal DiseaseScynexis developed its investigational fungal compound, SCY-247, which is in phase 1 clinical trials, and the company expects to share top-line data this year.
Latest:
Expanded Treatment Options for Multi-Drug Resistant Infections in ChildrenIn the latest article from SIDP, here is a look at therapy options addressing this emerging clinical challenge.
Latest:
How Do You Measure the Success of Your Stewardship Program?The challenging search for a metric that effectively evaluates an ASP’s direct impact on appropriate antimicrobial use and improved patient outcomes.
Latest:
First-Hand Insights into Treating Hepatitis C in PregnancyCatherine Chappell, MD, MSc, presents what we know so far, highlighting the safety and effectiveness of direct-acting antivirals, the importance of shared decision-making, and the need for patient-provider discussions to ensure informed choices about care.
Latest:
SURE1 and REASSURE Trials Paved Way for FDA Approval of OrlynvahCorey Fishman and Steven Aronin, MD, discussed trial highlights of Orlynvah for uncomplicated urinary tract infections and outlining plans to seek partners for a market launch to address antibiotic resistance and enhance patient treatment options.
Latest:
Early-Stage Antibiotic for Bone and Joint Infections Comparable to Standard of Care TherapyA small phase 2 study evaluated Debiopharm’s investigational antibiotic, afabicin, including its clinical response rate and safety profile of 2-3 weeks of treatment for staphylococcal bone and joint infections (BJI).
Latest:
Clinical Strategies for Tick Season: Lyme Prevention and Next-Gen DiagnosticsVibrant Wellness’ Jason Barker, ND, outlines prevention measures, diagnostic red flags, and advances in multiplex testing for tick-borne diseases.
Latest:
Cautionary Tale Associated in Trial With Rare Error in Cox RegressionInflaRx CEO Niels Riedemann, MD, discusses the issue that arose and cost the company some of its data for its investigational therapy being studied for SARS-CoV-2-induced acute respiratory distress syndrome (ARDS).
Latest:
Pandemic Preparedness: How Immunomics Technology is Leading the WayThe COVID-19 pandemic underscored the urgent need for global pandemic preparedness. The World Health Organization (WHO) is leading efforts to establish a global treaty to address future pandemics, with findings expected in 2025. Central to this preparedness is immunomics, a field leveraging advanced genomics technologies to study the immune system at unprecedented levels of detail.
Latest:
Respiratory Virus Season: Colds and COVID-19 UpdateWill this winter bring the feared twindemic of SARS-CoV-2 and influenza, or will another common infection reemerge?
Latest:
Reviewing the Efficacy and Safety of Omadacycline in Immunocompromised PatientsIn a new study presented at MAD-ID, omadacycline was found to have an 86% clinical success rate across a wide-range of infections and pathogens in an immunocompromised population.
Latest:
The NanoVax Vaccine Platform: Pandemic Preparedness and the Role of Mucosal ImmunityChad Costley, MD, MPH, discussed the platform's ability to respond to emerging respiratory diseases and the challenges in advancing mucosal vaccine development for health preparedness.
Latest:
HIV Prevention: Discussing PrEP, PEP, and Vaccine DevelopmentColleen Kelley, MD, MPH, offers some insights on where we are today with the state of HIV prevention including the expanding PrEP options, why PEP is underutilized, and the challenges behind HIV vaccine development.
Latest:
Looking Toward the Future of CDI ManagementClosing out their discussion on Clostridioides difficile infection, panelists share closing thoughts on novel pipeline therapies.
Latest:
A Viral Colonial Legacy: HIV, Monkeypox Emerged Due to Ongoing Colonial Viral NeglectSimilar to HIV, the colonial and postcolonial history is fundamental to the biology of this monkeypox outbreak.
Latest:
Wiki-What? Navigating WikiGuidelines and Leveraging Their AdvantagesWikiGuidelines produces novel clinical practice guidelines developed with pragmatic, applicable methodology, including a diverse author group.
Latest:
Bacterial Coinfections Among US Patients With Coronavirus Disease 2019Implications for antimicrobial use and antimicrobial resistance.
Latest:
NDM-Producing E coli Harboring PBP Insert Variants Emerges as New ThreatAs with other metallo-β-lactamases, NDM is capable of hydrolyzing nearly all β-lactams, including carbapenems, and the search for the proper antimicrobials is challenging.
Latest:
Addressing Neonatal CNS Infections: Case Report of Ceftaroline Therapy in Preterm Infant With Ventriculosubgaleal ShuntHere is a novel use of ceftaroline to treat methicillin-resistant Staphylococcus epidermidis ventriculitis in a preterm infant with a ventriculosubgaleal shunt.
Latest:
Addressing Neonatal CNS Infections: Case Report of Ceftaroline Therapy in Preterm Infant With Ventriculosubgaleal ShuntHere is a novel use of ceftaroline to treat methicillin-resistant Staphylococcus epidermidis ventriculitis in a preterm infant with a ventriculosubgaleal shunt.
Latest:
Simplified Hepatitis C Protocols Raise Treatment Uptake and Cure RatesSarah Rowan, MD, on minimal laboratory testing, Hepatitis B screening flexibility, peer navigation, and state‑specific strategies to overcome outreach and reimbursement hurdles
Latest:
Examining RSV Vaccines for SeniorsTwo RSV vaccines for seniors were FDA approved this year and here is an overview of the vaccines and the study data.
Latest:
Varicella Zoster Virus and Human Papillomavirus Vaccination in Immunocompromised PatientsVaccination for VZV and HPV requires special consideration in immunocompromised patients. They are at risk for more severe viral illnesses if not immune, but they may also have decreased response to, and increased adverse effects from, vaccines.
Latest:
Optimizing Vancomycin Therapy: A Review of AUC Calculation TechniquesThe ideal parameter for vancomycin monitoring is the area under the curve, which can be calculated using pharmacokinetic equations or Bayesian software.
Latest:
Antimicrobial Stewardship in the Era of Multidrug-Resistant InfectionsHere are some strategies to consider for optimal utilization.
